A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) (SurfSubQ)

Roche

Status: Enrolling

Conditions: Multiple Sclerosis

Treatments: Drug: Ocrelizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT06780150

ML45551

Details and patient eligibility

About

The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneous (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).

Enrollment: 842 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of MS
• RMS and PPMS participants diagnosed according to the McDonald criteria of 2017
• First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab

Exclusion criteria

• Participation in interventional studies investigating DMTs for MS
• Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site
• Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®)
• Severe psychiatric disability
• Pregnant women

Trial design

842 participants in 1 patient group

Ocrelizumab

Description:

Participants who are receiving ocrelizumab, SC injection, for the first time as part of their routine MS therapy at physician's discretion in accordance with local clinical practice and/or labeling will be observed for treatment satisfaction with SC injection for up to 12 months.

Treatment:

Drug: Ocrelizumab